Section 3 of 6
Product information and disease description
171 evidence topics · 77 sources
Product description
Phase of product development
FDA acceptance of the New Drug Application with Priority Review
Regulatory status: Under review; NDA submitted June 2026
Sponsor statement of the review acceptance and decision timing
Fast Track and Orphan Drug designations
European Union orphan designation
| Designation field | Quoted record |
|---|---|
| Active substance | “dersimelagon” |
| Intended use | “Treatment of erythropoietic protoporphyria” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/22/2585” |
| Date of designation | “16/03/2022” |
| Sponsor | “Tanabe Pharma GmbH” |
European Union submission route and expected registration
| Horizon-scan field | Quoted record |
|---|---|
| Registration route | “Centralised (EMA)” |
| Submission date | “July 2026” |
| Expected Registration | “August 2027” |
| Orphan drug | “Yes” |
Regulatory submission in Japan
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: LEO Pharma
Applicant of record and responsibility for United States approval
Transfer of worldwide rights from Tanabe Pharma to LEO Pharma
Generic name and therapeutic class
“Dersimelagon (formerly MT‐7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X‐linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proposed brand name
No evidence found.
Originator and change of corporate name
Dosage forms and strengths
Route of administration and formulation
Relative bioavailability of the tablet strengths studied
Commercial tablet strengths
No evidence found.
Average sales price and wholesale acquisition cost
United States wholesale acquisition cost and average sales price
No evidence found.
Expected annual cost per patient in the Dutch horizon scan
American hospital formulary service (AHFS), or other drug classification
American Hospital Formulary Service classification and WHO Anatomical Therapeutic Chemical code
No evidence found.
Drug class used as the cost analogue in the Dutch horizon scan
Indication
Indication stated in the United States filing announcement
Age range of the population studied in the phase 3 trial
Intended use and age scope recorded in European sources
Pharmacology
Mechanism of action
Induction of melanogenesis without sun exposure
“Dersimelagon (MT‐7117) is a novel synthetic, orally administered, nonpeptide small molecule that acts as a selective agonist of the melanocortin‐1 receptor, inducing melanogenesis in the absence of sun exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Preclinical melanogenesis in cell culture and animals
“The activation of melanocortin 1 receptor (MC1R) on melanocytes stimulates the production of eumelanin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In B16F1 cells, MT‐7117 increased melanin production in a concentration‐dependent manner. In vivo, MT‐7117 (≥0.3 mg/kg/day p.o.) significantly induced coat colour darkening in mice. MT‐7117 (≥1 mg/kg/day p.o.) induced significant skin pigmentation in monkeys and complete reversibility was observed after cessation of its administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MT‐7117 is a novel oral MC1R agonist that induces melanogenesis in vitro and in vivo, suggesting its potential application for the prevention of phototoxic reactions in patients with photodermatoses, such as erythropoietic protoporphyria and X‐linked protoporphyria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Melanin density after single and multiple doses in healthy participants
“No treatment-related effects on melanin density (MD) were observed following single doses of dersimelagon; however, after multiple doses, increases in MD were observed in participants receiving 150 and 300 mg dersimelagon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related increases in MD warrant further investigation in a larger study population and in patients with EPP and XLP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Absorption and dose proportionality in the first-in-human study
“In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the clinical trial, dersimelagon was rapidly absorbed following single oral doses, with exposure appearing to increase in a slightly more than dose-proportional manner, similar to that observed in rats following oral administration of dersimelagon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following multiple doses, dersimelagon was rapidly absorbed (median Tmax ranging from 4 to 5 h postdose on days 1 and 14). Mean t1/2 ranged from 10.56 to 18.97 h on day 14, and the steady state of plasma concentration was generally reached by 5 days of multiple dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonlinearity and effect of sex on exposure
“These studies showed that dersimelagon has a slightly nonlinear PK profile, with more than dose-proportional increases following single- or multiple-dose administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentrations were higher in females than in males and overall exposure was not significantly impacted by food intake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism and route of excretion
“In humans, elimination of radioactivity in urine was negligible (excretion of radioactivity into the urine: 0.31% of dose), and the primary route of excretion was feces, with more than 90% of the radioactivity recovered through 5 days postdose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Findings from humans and animals suggest dersimelagon is extensively metabolized to the glucuronide in the liver, which is eliminated in bile, and hydrolyzed to unchanged dersimelagon in the gut.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of food and of an acidic beverage on exposure
“No effect was observed on overall exposure (area under the plasma concentration versus time curve [AUC]) following consumption of a high-fat meal, and Cmax was higher (22%, 90% confidence interval [CI] 1.05-1.42) in a fed state compared with fasted conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In general, the consumption of an acidic beverage increased time to Cmax regardless of fed or fasted status and decreased overall exposure AUC and Cmax of dersimelagon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Approved labeling
No evidence found.
Dermatologic conditions excluded from the phase 3 trial
Adverse events reported in the phase 3 trial
Adverse events reported in healthy participants
“Dersimelagon was generally well tolerated in healthy participants, with the most common TEAEs being lentigo (52.8%) and skin hyperpigmentation (50.0%) after multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the incidence of TEAEs was relatively low, with most events occurring during Part A (SAD) and Part E (MAD) and the majority being mild to moderate in severity. No deaths or serious AEs were reported during any part of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These TEAEs related to changes in skin pigmentation may be attributable to the study drug based on the pharmacological effects of dersimelagon by virtue of its mechanism of action as a selective MC1R agonist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications
No evidence found.
Special populations
Hepatic impairment
“Participants with mild (n = 7) or moderate (n = 8) hepatic impairment or normal hepatic function (n = 8) received a single oral 100-mg dersimelagon dose. Participants with mild (n = 8), moderate (n = 8), or severe (n = 8) renal impairment or normal renal function (n = 8) received a single 300-mg dose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Systemic exposure to dersimelagon was comparable with mild hepatic impairment but higher with moderate hepatic impairment (maximum observed plasma concentration, 1.56-fold higher; area under the plasma concentration-time curve from time 0 extrapolated to infinity, 1.70-fold higher) compared with normal hepatic function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Renal impairment
“Maximum observed plasma concentration and area under the plasma concentration-time curve from time 0 extrapolated to infinity were similar with moderate renal impairment but higher with mild (1.86- and 1.87-fold higher, respectively) and severe (1.17- and 1.45-fold higher, respectively) renal impairment versus normal renal function. Dersimelagon was generally well tolerated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adolescents aged 12 to 17 years
Children younger than 12 years
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Dersimelagon
Verapamil and esomeprazole
“Dersimelagon exposure increased ~25% when co‐administered with verapamil, an effect not considered clinically relevant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, overall exposure AUC of dersimelagon was comparable following administration alone or in combination with esomeprazole; however, coadministration of esomeprazole led to a slight decrease in Cmax (fasted: 9%, 90%CI 0.77-1.07; fed: 24%, 90%CI 0.66-0.88) compared with administration of dersimelagon alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Dersimelagon on other drugs
Clinical drug interaction study with probe substrates
“Relatively potent in vitro inhibition of CYP2C9, CYP3A, UGT1A1, BCRP, P‐gp, and OATPs by dersimelagon was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Midazolam (CYP3A substrate), digoxin (P‐gp), pravastatin (OATP), and simvastatin (CYP3A) did not show any clinically relevant DDI effects when co‐administered with dersimelagon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dersimelagon 300 mg did not elicit major DDIs involving CYP/UGT enzymes and drug transporters; however, dersimelagon may have potential for clinically relevant DDIs with drugs that are substrates for BCRP, such as atorvastatin and rosuvastatin, and caution should be exercised when co‐administering 300‐mg dersimelagon with these statin drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predicted statin exposure at the clinical doses
“In vitro studies showed that dersimelagon is a weak, reversible, competitive and time‐dependent inhibitor of cytochrome P450 3A4 (CYP3A4), as well as a potential inhibitor of efflux and uptake transporter proteins, such as P‐glycoprotein (P‐gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3), organic anion transporters 1 (OAT1) and 3 (OAT3), and multidrug and toxin extrusion 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The systemic exposure of atorvastatin based on the maximum plasma concentration and area under the plasma concentration–time curve was predicted to increase 1.21‐fold and 1.25‐fold, respectively, if coadministered with dersimelagon 100 mg, and 1.42‐fold and 1.45‐fold with dersimelagon 200 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, PBPK modelling results indicate that the simulated changes in plasma exposure of atorvastatin and rosuvastatin following coadministration with dersimelagon 100 or 200 mg are not clinically significant, but caution and appropriate clinical monitoring should be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing and administration
Dosage
Dose studied in the phase 3 trial
Dose used in the long-term extension study
Administration
Administration with respect to food
“No effect was observed on overall exposure (area under the plasma concentration versus time curve [AUC]) following consumption of a high-fat meal, and Cmax was higher (22%, 90% confidence interval [CI] 1.05-1.42) in a fed state compared with fasted conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
No evidence found.
Co-prescribed/Concomitant therapies
Concomitant therapies restricted in the phase 3 trial
Sunscreen use permitted alongside treatment
Background preventive measures that continue during treatment
“Current approaches to the management of EPP and XLP are primarily limited to preventive measures, including sun avoidance and use of protective clothing and sunscreens, posing a substantial burden to patients by requiring significant lifestyle adjustments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of Dersimelagon on quality measures
No evidence found.
Product comparison
Summary: products approved or in late-stage development for these disorders
Afamelanotide is the only approved product. It shares dersimelagon's target, the melanocortin 1 receptor, but is given as a 16 mg fixed-dose subcutaneous implant every 2 months by a trained and accredited implanter, is indicated for adults with erythropoietic protoporphyria only, and has no established safety or effectiveness in patients under 18 years. Two investigational products act on protoporphyrin IX rather than on pigmentation. Bitopertin, a glycine transporter 1 inhibitor taken orally, lowers whole-blood metal-free protoporphyrin IX; its application for accelerated approval received a complete response letter in February 2026 after the Food and Drug Administration concluded that the phase 2 trials did not show an association between the change in protoporphyrin IX and sunlight-exposure endpoints, and its phase 3 APOLLO trial is ongoing. PORT-77, an oral ABCG2 inhibitor, reduced plasma protoporphyrin IX in a phase 2a study and entered phase 2b/3 in September 2026. No head-to-head trial, network meta-analysis, or indirect treatment comparison exists across these products, and each program uses a different primary endpoint, so relative efficacy cannot be estimated from the published evidence.
Mechanistic distinction between symptomatic and protoporphyrin-lowering products
“While afamelanotide and dersimelagon are symptomatic treatments, bitopertin and cimetidine aim to decrease blood PPIX concentration which makes them potentially causative treatment options” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our search in the clinical trials registries retrieved 29 trials that included patients with EPP. From these, we identified 16 clinical trials evaluating afamelanotide and three new pharmacotherapies, i.e., dersimelagon, bitopertin and cimetidine. Safety and efficacy of all new pharmacotherapies are currently being investigated against placebo-control groups or against baseline. Because of differences in the outcome measures and included patient populations, the results of the trials cannot be directly compared.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory status of bitopertin
Phase 3 trial of bitopertin
Phase 2 results for bitopertin
“Patients received bitopertin 20 mg (n = 26), 60 mg (n = 25), or placebo (n = 24). At day 121, the percentage change from baseline in whole-blood metal-free protoporphyrin-IX versus placebo was -29.6% (P = .004) with bitopertin 20 mg and -49.8% (P < .001) with bitopertin 60 mg. Bitopertin was associated with a reduced incidence of phototoxic reactions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Development status of PORT-77
Expedited designations granted for PORT-77
Absence of comparative evidence
“The currently available trial data on dersimelagon and bitopertin suggests treatment effects in EPP as compared to placebo control groups. However, safety and efficacy of dersimelagon and bitopertin need to be further characterized. Moreover, to ensure benefit for patients and access to therapy after regulatory approval, it also would be important to generate data on the relative safety and efficacy as compared to afamelanotide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition of erythropoietic protoporphyria
Definition of X-linked protoporphyria and expression in heterozygous females
Enzymatic basis: ferrochelatase deficiency and ALAS2 gain of function
“In EPP, autosomal recessive pathogenic variants in ferrochelatase (FECH) result in deficient activity of FECH, the last enzyme in the heme-biosynthetic pathway, leading to the accumulation of metal-free protoporphyrin in erythroid cells” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In XLP, gain-of-function variants in 5′-aminolevulinate synthase 2 (ALAS2) lead to overproduction and accumulation of metal-free and zinc protoporphyrin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autosomal recessive inheritance and the low-expression FECH allele
Population frequency of the low-expression allele
“Approximately 5%–10% of the European Caucasians population is a carrier for the low expression allele, which is even more prevalent in Japan (43%), and southeast Asia (31%), and practically absent in populations of sub‐Saharan origin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Homozygosity for the low-expression allele does not cause disease
Genetic basis and inheritance of X-linked protoporphyria
Epidemiology
Incidence of Erythropoietic protoporphyria or X-linked protoporphyria
Estimated incidence and rank among the porphyrias
Incidence in the Italian national porphyria network, 1996 to 2017
Incidence of X-linked protoporphyria
No evidence found.
Prevalence of Erythropoietic protoporphyria or X-linked protoporphyria
Reported prevalence range and sex distribution
Prevalence of the protoporphyria group and the X-linked share
“The protoporphyrias are a group of three ultra‐rare genetic disorders of the erythroid heme biosynthesis (prevalence between 1:75000 and 1:100000), all leading to the accumulation of protoporphyrin IX (PPIX) in erythrocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 4%–10% of protoporphyria patients suffer from XLEPP, which shows an X‐linked dominant inheritance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States patient count and X-linked share of cases
Genetic prevalence in the UK Biobank exceeds diagnosed prevalence
“Based on the incidence of EPP in Europe, the prevalence of EPP was estimated to be 0.00092%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of pathogenic FECH variants in the UK Biobank provides evidence that EPP prevalence is 0.0059% (95% CI: 0.0042%−0.0076%), 1.7–3.0 times more common than previously thought in the UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosed compared with exome-based prevalence
Heterogeneity of prevalence between European countries
“The prevalence of erythropoietic protoporphyria (EPP) was less uniform between countries and, in some countries, exceeded previous estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the prevalence of EPP may be increasing due to improved diagnosis and its greater recognition as a cause of photosensitivity” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
X-linked protoporphyria as a proportion of the protoporphyria phenotype in the United Kingdom and the United States
Observed diagnosis distribution in the United States natural history study
Genotype distribution in the Italian national cohort
Natural history, survival, and mortality
Age at symptom onset and lifelong persistence of photosensitivity
Frequency of hepatic dysfunction and progression to liver failure
“About 2–5% of patients develop clinically significant liver dysfunction due to protoporphyrin deposition in bile and/or hepatocytes which can advance to cholestatic liver failure requiring transplantation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transplantation, mortality, and cause of death in the United States longitudinal study
“In total, 54 (16.8%) underwent cholecystectomy, 8 (2.5%) had a liver transplant, 4 (1.2%) had a bone marrow transplant, and 8 (2.5%) died.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight (6 with EPP and 2 men with XLP) patients died; 4 due to liver failure, 2 (both with EPP) from complications related to BMT, and 1 due to HCC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the total, 3.4% of enrolled patients had histologic evidence of protoporphyric hepatopathy and 2.5% required liver transplantation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, at least 50% of the deaths that occurred in this cohort were attributable to liver involvement by these protoporphyrias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advanced hepatopathy by diagnosis
“A higher proportion of patients with XLP (1 male, 2 females) had advanced hepatopathy (3/27, 11.1%) compared with patients with EPP (8/294, 2.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Protoporphyric hepatopathy is rarely recognized at an early stage, and much of its natural history remains poorly understood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver transplantation is not curative
“Liver transplantation can be lifesaving but is not curative and may be followed by allogeneic hematopoietic stem cell transplantation, which restores marrow FECH activity to ameliorate injury to the transplanted liver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Protoporphyrin IX accumulation and photoactivation in dermal vasculature
“Protoporphyrin is believed to be taken up from plasma by vascular endothelial cells in the skin where photoactivation by visible light leads to the formation of reactive oxygen species that cause cellular damage, inflammation, and cutaneous phototoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Action spectrum: the Soret band near 400 nm
Complement activation and mast cell degranulation
“Thunell et al., in 2000, first hypothesized that PPIX excitated at 410 nm leads to singlet oxygen (1O2*) mediated damage of endothelial cells” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The photodamage leads to the stimulation of an inflammatory response, occurring via complement system (CS) activation and mast cell degranulation, with exocytosis of vasoactive mediators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dissociation between pain and visible skin change
Biliary excretion of protoporphyrin and hepatobiliary injury
Diagnosis
Erythrocyte protoporphyrin with metal-free and zinc fractionation as the recommended test
“Total erythrocyte protoporphyrin concentration, including proportions of metal-free and zinc-bound protoporphyrin, is the recommended test for the diagnosis of protoporphyria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of metal-free protoporphyrin is typically >90% in EPP and ~50–85% in XLP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic threshold and biochemical discrimination of the two disorders
“A metal‐free PPIX ≥3 times the upper limit of normal (ULN) establishes the diagnosis of protoporphyrias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, XLEPP can usually be distinguished biochemically from EPP1 by the higher proportion of ZnPP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercial assays that measure zinc protoporphyrin can miss the diagnosis
“Some major commercial labs, such as Quest and LabCorp, provide a “free erythrocyte protoporphyrin” test, which is actually a zinc protoporphyrin test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because zinc protoporphyrin is often normal in EPP, the diagnosis may be missed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing to distinguish the two disorders
Diagnostic delay
“The mean diagnostic delay is over a decade, and evidence supports significant underdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean number of years between initial symptoms and diagnosis of EPP was 13 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority (76%) presented with symptoms of EPP before four years of age” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Holme et al identified 389 patients with EPP in the UK; the median ages at symptom onset and diagnosis were one and 12 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Wahlin et al identified 51 patients with EPP in Sweden; the median ages at onset and diagnosis were one and 22 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misattribution of symptoms before diagnosis
“Thirty eight percent of patients saw five or more physicians prior to being diagnosed with EPP; of those, 22% saw more than 10 physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior to diagnosis, the majority of individuals were thought to have a sun allergy (50%), or another type of allergic reaction (16%); 15% of individuals were thought to have a psychological issue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Cutaneous symptoms: prodromal tingling, burning, and phototoxic pain
“Patients typically present in childhood with prodromal symptoms, including tingling, itching, and burning on sun exposure, which is followed by severe, prolonged phototoxic pain and swelling unless exposure is interrupted. Symptom onset is typically within 10–30 minutes of exposure to visible light.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the most commonly reported EPP symptoms after sun exposure were cutaneous burning (289, 89.8%), swelling (273, 84.8%), and tingling (252, 78.3%), and 176 (54.7%) reported a time-to-first symptom of <30 minutes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Phototoxic reactions were characterized by pain (97%; 34 patients), burning (97%; 34), tingling (97%; 34), pruritus (83%; 29), allodynia (89%; 31)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prodromal (early warning) symptoms after sunlight exposure, reported by > 50% of participants, included tingling, warmth, itching, sensitivity to touch, and burning; symptoms occurred in ≤ 10 min in 48.8% of adults and 15.2% of adolescents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“67.1% of adults and 87.9% of adolescents experienced ≥ 1 phototoxic reaction in the previous 12 months” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cutaneous symptoms: escalation with continued exposure and the priming phenomenon
“Early symptoms often manifest within a few minutes of light exposure as tingling, itching or burning, which intensify with prolonged light exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Repeated light exposure can increase light sensitivity, the so‐called ‘priming phenomenon’.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cutaneous symptoms: delayed and often absent visible skin change
Cutaneous symptoms: chronic changes of sun-exposed skin
Hepatobiliary symptoms: aminotransferase elevation and gallstones
“Previous studies in cohorts from the United States and Europe have shown elevated serum aminotransferases in 25%–27% of patients with EPP and XLP, and an increased prevalence of cholelithiasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the time of enrollment, 49 patients (15.2%) had a history of cholecystectomy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gallstones were commonly reported in patients with EPP or XLP (13.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatobiliary symptoms: liver enzyme, steatosis, and fibrosis findings in a Dutch cohort
“Elevated liver enzymes were found in 6.2% of the patients. Liver steatosis was detected in 29.0%, and significant fibrosis as assessed with liver stiffness measurements was present in 9.6% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hepatobiliary symptoms: higher frequency of abnormal liver enzymes in X-linked protoporphyria
Hematologic symptoms: microcytic anemia and iron deficiency
“A mild hypochromic, microcytic anemia is present in ~30–60% of patients with protoporphyria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anemia (107 [47.3%]), history of liver dysfunction (62 [27.4%]), and gallstones (53 [23.5%]) were commonly reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anemia was present on self-reported medical history in 145 (45.0%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“it is estimated that 20%–60% of EPP patients develop mild microcytic anemia whose pathogenesis is unclear” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, all microcytic patients showed PPIX mean levels significantly higher than normocytic patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic and bone symptoms: vitamin D deficiency from lifelong sunlight avoidance
“There is an increased recognition of prevalence of vitamin D deficiency in protoporphyria patients due to lifelong sunlight avoidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Multisystem course requiring longitudinal monitoring
Range of long-term complications
“The complications associated with the protoporphyrias are diverse and include protoporphyria‐related liver failure, gallstones, iron deficiency and vitamin D deficiency, with related reduced bone mineral density and fracture risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduced bone mineral density and fracture burden
“BMD is low in EPP patients, with 82.7% of the 139 patients having a Z-score below 0 SD at baseline. Low BMD classified as osteopenia was found in 39.5%, and osteoporosis in 15.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 50 osteoporosis-related fractures in 34.2% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals aged 50 years and older, the prevalence of osteoporosis in EPP patients was much higher at 33.3% compared with 6.3% to 14.3% in the general European population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Greater burden among those with liver disease
“The significant burden imposed by EPP appears to be greater among those with self‐reported liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among a total of 164 adult participants, 25 (15.2%) self‐reported liver disease and 139 did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Erythropoietic protoporphyria or X-linked protoporphyria
Humanistic burden and health-related quality of life
Tolerated sunlight exposure before symptom onset
“Severity is variable, but most patients can only tolerate <30 minutes of sun exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interference with daily activities, school, and work
“Prodromal (early warning) symptoms after sunlight exposure, reported by > 50% of participants, included tingling, warmth, itching, sensitivity to touch, and burning; symptoms occurred in ≤ 10 min in 48.8% of adults and 15.2% of adolescents. Symptoms hindered daily activities at least "somewhat" for 62.8% of adults and 87.9% of adolescents, and 23.4% - 41.7% reported school/work absenteeism in past month; 67.1% of adults and 87.9% of adolescents experienced ≥ 1 phototoxic reaction in the previous 12 months” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-four percent (53.7%; adults) and 16.7% (adolescents) reported work productivity was affected by their EPP at least "a little bit” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Emotional and psychological effects
“Most adults and adolescents reported feeling depressed (75.0%, 45.5%), anxious (79.9%, 60.6%), isolated (82.9%, 57.6%), frustrated (90.2%, 93.9%), and lonely (75.6%, 39.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The HADS was completed by 103 patients (95 EPP, 8 XLP), and mean scores for anxiety and depression were within the normal range (Table 3 ); however, 20% (21/103) of patients had borderline or abnormal anxiety levels, and 9.7% (10/103) had borderline or abnormal depression levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment and social functioning
“The educational level of EPP patients seemed higher compared to the Dutch population (36% vs. 30% high-education, 42% vs. 37% middle-education). At baseline 5% of the EPP patients were unemployed, none were unemployed during afamelanotide treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“EPP patients scored low on the social functioning domain (SF-36) compared to the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4; respectively), and improved during afamelanotide treatment (84.3 ± 20.9, p = 0.001). EPP has a significant negative impact on social aspects, with less employment despite a higher education level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Performance of quality-of-life instruments in this disease
“Impaired QoL is an important consequence of EPP/XLP. PROMIS-57 was most sensitive in evaluating impaired QoL in EPP/XLP. Further research is needed to compare the effectiveness of it for assessing response to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of scores indicating >1 SD of impairment, which can be considered clinically significant, are shown in Table 2 ; notably 21.8% (42/193) of patients have clinically significant pain interference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QoL was markedly impaired, with scores similar to those in severe dermatological disease (mean DLQI score 14.0, n = 176; mean CDLQI score 12.8, n = 44), indicating a large effect on patients' lives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 3 factors from the EPIQ demonstrated acceptable to strong psychometric properties in terms of reliability (internal consistency, test-retest), validity (construct, known groups), and responsiveness. Ranges for meaningful change, using anchor- and distribution-based approaches, were established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adaptation confounds measurement of quality of life
“Patients with EPP are highly adapted to their condition which makes the quantification of their health-related quality of life (QoL) challenging.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QoL under treatment was comparable to the age-matched population norm, and retrospective results for a treatment interruption and phototoxic reaction time point were comparable to the QoL of patients with chronic neuropathic pain and acute burn injuries, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life in children
“Children with EPP exhibited lower median scores in the PedsQL in both physical (cases: 87.5 (interquartile range [IQR] 77.7-96.1), controls: 99.2 [IQR 94.9-100.0], p = 0.03) and social (cases: 77.5 [IQR 69.4-86.3], controls: 97.5 [IQR 78.8-100.0], p = 0.04) domains compared to healthy children” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, children with EPP experience a reduced QoL compared to both healthy children and adults with EPP. Ensuring treatment availability for this patient group is crucial for improving their QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Resource use and total cost compared with matched comparators
“Over a mean follow-up of 30 months, patients with EPP/XLP had significantly higher all-cause HRU compared with comparators, with a mean PPPY number of inpatient stays of 0.8 vs 0.2 (RR = 3.4; P < 0.001), emergency department visits of 1.5 vs 0.9 (RR = 1.7; P = 0.002), and outpatient visits of 35.2 vs 17.5 (RR = 2.0; P < 0.001). All-cause costs were also significantly higher among patients with EPP/XLP compared with comparators with a mean PPPY total cost of $71,714 vs $18,646 (ratio = 3.9; P < 0.001), driven by inpatient costs (mean = $30,909 vs $6,318; ratio = 4.9; P < 0.001) and outpatient costs (mean = $33,416 vs $7,573; ratio = 4.4; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease-specific and comorbidity-related cost components
“Medical costs related to EPP/XLP-associated comorbidities PPPY among patients with EPP/XLP were nearly 6 times those among matched comparator patients (mean = $25,611 [SD = $173,731] vs $4,298 [SD = $30,562]; cost ratio = 5.96; P < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and represented almost 40% of the total all-cause medical costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with EPP/XLP, the mean total EPP/XLP-specific medical costs PPPY were $17,448 (SD = $90,366), approximately one-fourth of total all-cause health care costs, and were mainly driven by EPP/XLP-specific OP costs (mean = $14,534 [$83,836” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medication use in the absence of disease-directed therapy
“Although only 7.6% of patients with EPP/XLP received treatment for EPP/XLP, most commonly afamelanotide (3.9%), most (68.4%) used medication related to EPP/XLP-associated comorbidities, including narcotics (46.3%), nonsteroidal anti-inflammatory drugs (38.2%), and antidepressants (35.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration of burden among adolescents
“This study found that patients with EPP/XLP have significantly higher health care use and costs compared with those without the condition. Few patients received treatment for EPP/XLP, and the economic burden was particularly high among adolescents, who currently have no approved therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adolescent subgroup included 28 patients with EPP/XLP and 112 matched comparator patients. Descriptive results in this subgroup (not compared statistically because of the low sample size) show that these patients also incurred numerically higher HRU and costs compared with the matched comparator cohort with relative rates and cost ratios even higher than those observed in the overall sample (all-cause IP stays: RR = 14.72; days hospitalized: RR = 28.86; ED visits: RR = 1.48; OP visits: RR = 3.19; and total all-cause health care costs: cost ratio = 16.36 in the adolescent subgroup” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported visit frequency
Higher resource use among those with liver disease
“EPP-related HCU in the previous 12 months was higher for those with liver disease than those without liver disease, including more physician visits (mean of 16.5 versus 6.0) and emergency room visits (mean of 9.0 versus 1.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Encounter counts and cost in a medical-record cohort
“Within 12 months of diagnosis, the mean (SD; median) number of office visits, emergency department visits, and inpatient hospitalizations related to EPP or XLP were 4.0 (3.5; 3.0), 0.8 (1.6; 0), and 0.4 (1.3; 0), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient hospitalizations and ED encounters specifically related to EPP or XLP were seen in fewer than 40% of patients. However, these encounters were costly, resulting in a mean cost of approximately USD2700 per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monetized indirect costs and productivity loss
No evidence found.
Economic impact of Erythropoietic protoporphyria or X-linked protoporphyria on families
Quantified family out-of-pocket costs and caregiver productivity loss
No evidence found.
Family adjustments described by parents of affected children
“All parents described a frustrating diagnostic odyssey before their child was finally diagnosed with EPP. They all agreed they felt relief following the diagnosis of EPP in their children, as well as validation that their child's symptoms were real.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Parents had to make adjustments to their family's lives to accommodate for EPP such as driving to places in two separate cars, one with window tints and one without, and planning family activities outdoors in the evening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most parents thought that their children initially struggled with fitting in socially, specifically at school, as they were physically isolated during activities such as recess, which resulted in social isolation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time lost from work and school in households affected by liver disease
Education of the family and school environment as a component of care
“It is crucial and complex for protoporphyria patients and their families to inform and educate their social network, to raise awareness and understanding of the limitations and the necessary support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Supporting the patients and their families in educating them about their social, school and work environments is an important part of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Measured cost of the diagnostic pathway
“Average costs from symptom onset to diagnosis of EPP or XLP were approximately USD600 per patient. Once diagnosed, average costs of referrals and tests in the first year were approximately USD400 across all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) number of specialist referrals before diagnosis was 2.8 (3.6) with a median of 2.0. Referrals were primarily to dermatologists (48%) and hematologists (22%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data on the number of pre-diagnostic tests were not collected; thus, the analysis assumed only 1 test per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Testing that guidelines recommend against
“Clinicians should avoid laboratories that measure protoporphyrin only by hematofluorometry, which can lead to falsely normal levels of erythrocyte protoporphyrins, and these results are often incorrectly labeled as “free erythrocyte protoporphyrin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with protoporphyria, plasma porphyrin levels may be normal or increased” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elevated plasma porphyrins are not diagnostic of EPP and are therefore not recommended as first-line testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urinary and fecal porphyrins are typically normal in protoporphyria, and testing is not recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skin biopsies are not indicated for the diagnosis of protoporphyria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic testing in the absence of biochemical testing is not recommended given the possibility of identifying variants of uncertain significance and the small percentage of patients in whom the genetic variant remains undefined” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Specialized laboratory required for confirmatory testing
“In general, the biochemical analyses should be performed in a laboratory acknowledged as a specialized centre for porphyrin diagnostics, such as the laboratories certified by the International Porphyria Network (Ipnet, formerly known as European Porphyria Network; porphyrianet.org.).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of genetic testing and of misdiagnosis
No evidence found.
Approaches to treatment
Current treatment options and standard of care
Sunlight avoidance and photoprotective measures
Guideline recommendation for avoidance, clothing, and tinted sunscreens
“Sunlight avoidance and opaque clothing are recommended for the prevention of phototoxic symptoms in protoporphyria ( Table 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Window tinting for cars can be useful” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because some patients report a small benefit with broad-spectrum and/or tinted sunscreens such as zinc oxide and titanium dioxide and because these agents block a portion of the far UVA wavelengths (350–399 nm) of light that activate protoporphyrin, it is reasonable for patients to use these agents for the prevention of phototoxic symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, non-broad-spectrum or non-tinted sunscreens are not useful for prevention of phototoxic symptoms in protoporphyria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depending on symptom severity, workplace/school accommodations and educating teachers about protoporphyria can be useful, as well as educating children regarding how to explain their disease and to advocate for themselves” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Behavioral adaptation as the default in the absence of treatment
“Without access to specific treatment options that prevent or treat phototoxic reactions, patients can only adapt their behaviour by avoiding activities outdoors in sunlight and by using light filters and photo-protective clothing consisting of opaque clothing with long sleeves, headwear, gloves, enclosed footwear and shields, even during the winter months. Given the early onset of the protoporphyrias and the diagnostic delay, most patients are already conditioned to avoid (sun)light before their diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advice recorded in a United States medical-record cohort
Melanocortin 1 receptor agonists
Approved indication and administration of afamelanotide
European prescribing restrictions and authorisation basis for afamelanotide
Randomized trial results for afamelanotide
“In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P=0.04). In the European Union study, the duration of pain-free time after 9 months was also longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P=0.005), and the number of phototoxic reactions was lower in the the afamelanotide group (77 vs. 146, P=0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Observational effectiveness of afamelanotide
“A total of 117 patients with EPP (59 women [50.4%]; mean [SD] age, 43.0 [15.5] years) were treated with afamelanotide. Nearly all patients continued treatment (115 [98%]) with a median (interquartile range) follow-up of 2.0 (1.3-2.1) years. Compared with baseline, mean time spent outside during treatment increased significantly by an added 6.1 hours per week (95% CI, 3.62-8.67; P < .001). Mean quality of life score improved significantly by 14.01% (95% CI, 4.53%-23.50%; P < .001). Phototoxic reactions were less painful (β, -0.85; 95% CI, -1.43 to -0.26; P < .001), but there was no significant difference in number or duration of reactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The quality of life (QoL) scores, measured by an EPP-specific questionnaire, were 31 ± 24% of maximum prior to afamelanotide treatment, rose to 74% after starting afamelanotide and remained at this level during the entire observation period. Only minor adverse events attributable to afamelanotide, predominantly nausea, were recorded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline position on afamelanotide
“Therefore, afamelanotide is recommended for the prevention of phototoxic symptoms in EPP ( Table 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients using afamelanotide, total body skin examinations by a dermatologist are recommended every 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The drug is available in the US and Europe, however access is limited in the US due to the high cost and restricted sites for administration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no data on the safety of afamelanotide during pregnancy so this cannot be recommended for pregnant women” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Observed treatment duration and adherence in United States claims data
“Among the 27 patients with EPP/XLP who used afamelanotide during the follow-up period, the median duration of treatment was 5.68 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean PDC was 0.74 (SD = 0.23) at 6 months, 0.68 (SD = 0.21) at 12 months, and 0.63 (SD = 0.29) at 24 months, and only 39%-50% of patients had PDC greater than or equal to 0.8 in these periods” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative global exposure to afamelanotide
Oral antioxidants and other systemic agents
Agents that guidelines do not recommend
“Due to insufficient data related to efficacy, the following therapies are not recommended for the prevention of phototoxic symptoms: beta-carotene, cysteine, cimetidine, isoniazid, warfarin, quinacrine, oral zinc, N-acetylcysteine, vitamin C, omega-3 fatty acids, oral adenosine monophosphate, canthaxanthine, terfenadine, inosine, dithiothreitol (DTT) and glycerol, pyridoxine, and hydroxyethylrutosides ( Table 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although several previous studies have investigated beta carotene in EPP, the evidence shows unclear or no benefit” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is an extensive and complete review on previous drugs such as beta‐carotene and cimetidine;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“however, none of these have any significant effect on protoporphyrias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continued use despite the absence of supporting evidence
“Following diagnosis, most patients were advised to prevent phototoxic reactions by avoidance of sun exposure and use of sunscreen; 40% were prescribed beta-carotene despite insufficient data regarding its efficacy. Further, despite studies showing that non-steroidal anti-inflammatory drugs provide little symptom relief, a third of the sample received recommendations for these drugs for EPP or XLP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phototherapy and sunlight hardening
Guideline position on narrowband ultraviolet B phototherapy
“For patients without access to afamelanotide, limited natural sunlight exposure or low-dose hardening phototherapy with narrowband UVB increased slowly over time to induce a gradual increase in endogenous melanin production may be considered for prevention of phototoxic symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However the effectiveness of this therapy is unclear and not well established” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who are sensitive to indoor lighting, utilizing indoor lights that minimize the amount of blue light may be considered” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Management of acute phototoxic reactions
Absence of an effective treatment for an established reaction
“No studies evaluating treatments for acute phototoxicity could be found” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anecdotally, many patients choose to self-treat with ice, cold water, or cold compresses, resulting in minor relief, although others report that both cold and heat worsen symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cold compresses or cooling devices may be considered for the treatment of phototoxic symptoms ( Table 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no evidence of benefit with narcotic analgesics, oral or topical corticosteroids, antihistamines, acetaminophen and non-steroidal anti-inflammatory drugs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are insufficient data to recommend these therapies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The development of novel therapies to treat pain in protoporphyria patients is a large unmet need” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Management of hepatobiliary complications
Course of protoporphyric hepatopathy and monitoring recommendation
“Approximately 1–5% of patients with protoporphyria develop rapid and severe hepatobiliary disease characterized by an acute cholestatic hepatitis with liver failure (often called “EPP hepatic crisis”), or a slowly progressive biliary cirrhosis and end stage liver disease; these more advanced manifestations of liver disease due to protoporphyria are collectively referred to as “protoporphyric hepatopathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These patients almost invariably require liver transplantation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, it is recommended that liver chemistries should be monitored at least yearly in patients with protoporphyria to detect early stages of liver dysfunction starting at the time of diagnosis of protoporphyria ( Figure 4” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend TPE for patients with advanced protoporphyric hepatopathy to decrease plasma porphyrin levels and thereby reduce liver damage in order to bridge patients to liver transplant and/or hematopoietic stem cell transplant (see below” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrent protoporphyric hepatopathy in the transplanted liver has been reported in 65 to 80% of patients in case series from the US, Australia, and Europe, with 43% showing evidence of recurrence by one year post-transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Escalating interventions for hepatic decompensation
“As a first measure, any hepatotoxins should be eliminated. Depending on the severity of the liver disease, phlebotomies, exchange transfusions and ultimately liver transplantation with subsequent haematopoietic stem cell transplantation (HSCT) are therapeutic options, whereby multidisciplinary management including porphyria experts is mandatory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genotype-dependent effect of iron supplementation
“In EPP1, even in cases of biochemically determined iron deficiency, supplementation of iron may stimulate PPIX production, resulting in an increase in photosensitivity and the risk of cholestatic liver disease. However, for patients with XLEPP, iron supplementation can reduce PPIX levels, phototoxicity and liver damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: constraints on the current standard of care
No therapy is approved for patients younger than 18 years, and afamelanotide, the only approved product, is indicated for adults with erythropoietic protoporphyria and not for X-linked protoporphyria. Afamelanotide is a fixed-dose subcutaneous implant administered every 2 months by a trained and accredited implanter at a recognized porphyria center, which limits dose adjustment and restricts the sites able to provide it. In a United States claims analysis of 696 patients with either disorder, 7.6% received any treatment for the condition and 3.9% received afamelanotide, with a median treatment duration of 5.68 months. Clinical practice guidelines recommend against beta-carotene, cysteine, cimetidine, and other systemic agents for prevention of phototoxic symptoms, and identify no effective treatment for an established phototoxic reaction. Sunlight avoidance remains necessary during treatment and is associated with vitamin D deficiency.
Absence of any approved pediatric therapy
“There are no approved therapies for pediatric patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“because of its mode of administration as a 16 mg fixed dose slow-release subcutaneous implant, dose-adjustments of the currently approved formulation of afamelanotide are not possible, which makes it unsuitable for the treatment of children. Afamelanotide is also not sufficiently effective or suitable for all adult patients, and, being a symptomatic treatment, does not address the increased risk for EPP-related liver failure. Moreover, because of lack of reimbursement, afamelanotide is not yet available to patients in many countries, despite being the only approved treatment for EPP” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration site and coverage restrictions
“The low number of afamelanotide users observed in this study, and the low duration of treatment and adherence, likely reflect both the restricted patient access limited to specific treatment centers authorized to administer afamelanotide as well as the strict insurance coverage criteria, including prior authorization, time-limited approvals for initial use, and requirements for evidence of clinical benefit to support continued treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guideline-recommended pharmacological management of EPP symptoms among adults is currently restricted to afamelanotide; however, this therapy is not indicated for pediatric patients or patients with XLP, and there are limitations to access to this drug because administration is restricted to specific centers. There is a clear need for additional efficacious and accessible treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Residual burden during treatment
Place in treatment, anticipated use, and care setting
Summary: anticipated position of an oral melanocortin 1 receptor agonist
Dersimelagon shares its mechanism with afamelanotide, the only approved therapy, but is taken as a once-daily oral tablet rather than a subcutaneous implant placed every 2 months by an accredited implanter. If approved on the submitted application, it would be the first therapy available to patients aged 12 to 17 years and the first approved specifically for X-linked protoporphyria as well as erythropoietic protoporphyria. The phase 3 INSPIRE population was treatment-naive for dersimelagon and excluded participants receiving other active treatment for either disorder, so no evidence describes use after or alongside afamelanotide. Care would remain specialist-led: clinical practice guidelines recommend annual liver chemistries, an annual complete blood count and iron panel, vitamin D screening, and total body skin examination every 6 months for patients receiving a melanocortin 1 receptor agonist.
Contrast in route of administration with the approved therapy
“Dersimelagon is a melanocortin receptor 1 (MC1R) agonist with a similar mode of action to afamelanotide. In contrast to afamelanotide, which has to be given as a subcutaneous implant, this drug is available in an oral form.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Protoporphyrin concentration as a marker of disease severity
“Higher ePPIX levels were associated with earlier age of symptom onset (median ePPIX levels for those who developed symptoms before vs after 1 year of age, 1744 vs 1567 µg/dL; P = .02), less sun tolerance (median ePPIX levels for those reporting symptoms before vs after 10 minutes of sun exposure, 2233 vs 1524 µg/dL; P ≤ .001), and increased risk of liver dysfunction (median ePPIX levels for those with liver dysfunction vs normal liver function, 2016 vs 1510 µg/dL; P = .003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Male patients with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 µg/dL; P < .001). Marked clinical variability was seen in female patients with XLP owing to random X-chromosomal inactivation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Greater effect in participants with higher baseline protoporphyrin in the phase 2 trial
Variability of severity in females with X-linked protoporphyria
Limits of protoporphyrin concentration for stratification
Variability in response to the approved comparator
Care management intervention strategies
Recommended laboratory monitoring
“Liver chemistries should be performed at the time of diagnosis and at least yearly thereafter ( Table 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the risk of iron deficiency and anemia, it is reasonable for patients to have an annual CBC and iron panel ( Table 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Routine screening for vitamin D deficiency and supplementation as per population guidelines are recommended ( Table 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genotype-directed iron repletion
Skin surveillance during melanocortin 1 receptor agonist therapy
Perioperative light filtering
Documentation supporting school and workplace accommodation
“Supportive care can include a document and/or medical alert card from the porphyria centre describing the medical condition, as well as the consequences of light exposure and the need for light protection. With these documents, patients can inform not only their peers, teachers and colleagues but also their health care providers, enabling a better understanding of the required adaptations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary: outcomes a melanocortin 1 receptor agonist is expected to change
Therapy with a melanocortin 1 receptor agonist is symptomatic. It is expected to increase the time a patient can spend in sunlight before symptoms begin, reduce the number of sunlight-induced pain events, and improve patient-reported global impression and quality of life. It is not expected to lower protoporphyrin concentrations or to alter the risk of protoporphyric hepatopathy, and sunlight protection measures continue during treatment. The regulatory precedent for the approved comparator used hours of direct sunlight exposure without pain as the primary endpoint; the dersimelagon program instead used minutes of daily sunlight exposure before the first prodromal symptom, so effect sizes are not directly comparable between the two products.
Pain as the clinically meaningful outcome in a symptomatic therapy
“Being a symptomatic treatment, afamelanotide does not affect quantifiable biomarkers or objectively quantifiable disease signs in EPP. However, a “reduction in pain” is clinically meaningful and the extend of the provided benefit can be assessed by the patients themselves, as opposed to, for example, surrogate endpoints that measure change in biomarker expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Differences in endpoints prevent cross-product comparison
“The primary endpoints used in the clinical trials investigating dersimelagon, bitopertin and cimetidine differ from each other, and from the endpoint used in the pivotal trial investigating afamelanotide in EPP. While some of the secondary endpoints assess the same aspects, the exact methods how the results were obtained need to be considered when comparing efficacy outcomes between the different interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote